Status:
COMPLETED
OSI-774 (Erlotinib, Tarceva) in Elderly Patients
Lead Sponsor:
Montefiore Medical Center
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
65+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to determine if OSI-774 (Tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects. The investigators would also ...
Detailed Description
In recent years, it has been shown that the degree of improvement achievable with chemotherapy has plateaued with the use of chemotherapy doublets. The presence of co-morbid conditions and poor perfor...
Eligibility Criteria
Inclusion
- Patients must have confirmed non-small cell lung cancer. Age \> 65 years Patients must have adequate organ and marrow function
Exclusion
- Patients who have had prior chemotherapy will be excluded. Patients may not be receiving any other investigational agents.
Key Trial Info
Start Date :
July 2 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 12 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00200395
Start Date
July 2 2003
End Date
January 12 2007
Last Update
December 30 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Medical Center
New York, New York, United States, 10003
2
New York University
New York, New York, United States, 10016
3
Albert Einstein Cancer Center
The Bronx, New York, United States, 10461
4
Montefiore Medical Center-
The Bronx, New York, United States, 10467